Arbutus Biopharma says presents 'encouraging' data on hepatitis B platform
Arbutus Biopharma announced data presentations at the American Association for the Study of Liver Diseases Meeting. "We are excited to present encouraging data that support the combination of two of our proprietary hepatitis B virus candidates: AB-423 and ARB-1740," the company remarked. The presentations include "Preclinical Studies with Capsid Inhibitor AB-423 and a siRNA Agent, ARB-1740," whose data "support the strategy of developing drug combinations to deliver a cure for chronic HBV infection." Additionally, regarding a presentation titled "AB-423 Exhibits a Dual Mode of Action and Displays Additive/Synergistic Effects in In Vitro Combination Studies," Arbutus said "AB-423 is a promising antiviral agent that exhibited potent inhibition of HBV replication in cell culture systems and showed a favorable antiviral activity profile when combined with nucleoside or RNAi agents in vitro. Mechanism of action studies showed that AB-423 is a potent inhibitor."